792 related articles for article (PubMed ID: 17898879)
1. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
Franzolini N; Quartuccio L; De Marchi G; De Vita S
Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
[TBL] [Abstract][Full Text] [Related]
2. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
Cavagna L; Caporali R; Abdì-Alì L; Dore R; Meloni F; Montecucco C
J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
[TBL] [Abstract][Full Text] [Related]
4. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.
Kameda H; Nagasawa H; Ogawa H; Sekiguchi N; Takei H; Tokuhira M; Amano K; Takeuchi T
J Rheumatol; 2005 Sep; 32(9):1719-26. PubMed ID: 16142867
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
[TBL] [Abstract][Full Text] [Related]
7. [The antisynthetase syndrome: a cause of rapidly progressive interstitial lung disease].
Jordan Greco AS; Métrailler JC; Dayer E
Rev Med Suisse; 2007 Nov; 3(134):2675-6, 2679-81. PubMed ID: 18159702
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset.
Tillie-Leblond I; Wislez M; Valeyre D; Crestani B; Rabbat A; Israel-Biet D; Humbert M; Couderc LJ; Wallaert B; Cadranel J
Thorax; 2008 Jan; 63(1):53-9. PubMed ID: 17557770
[TBL] [Abstract][Full Text] [Related]
9. [Idiopathic interstitial pneumonia: treatment].
Cottin V
Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S97-10S102. PubMed ID: 17127978
[No Abstract] [Full Text] [Related]
10. Advances in immunosuppressive therapy.
Marder W; McCune WJ
Semin Respir Crit Care Med; 2007 Aug; 28(4):398-417. PubMed ID: 17764058
[TBL] [Abstract][Full Text] [Related]
11. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.
Wilkes MR; Sereika SM; Fertig N; Lucas MR; Oddis CV
Arthritis Rheum; 2005 Aug; 52(8):2439-46. PubMed ID: 16052580
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
14. [Polymyositis and Jo-1 syndrome].
Treher E; Niederhoff A; Gellissen U; Schmidt P; Dornberg M; Peter HH
Z Rheumatol; 1993; 52(5):301-6. PubMed ID: 8259722
[TBL] [Abstract][Full Text] [Related]
15. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
16. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.
Goh NS; Veeraraghavan S; Desai SR; Cramer D; Hansell DM; Denton CP; Black CM; du Bois RM; Wells AU
Arthritis Rheum; 2007 Jun; 56(6):2005-12. PubMed ID: 17530640
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia.
Kondoh Y; Taniguchi H; Yokoi T; Nishiyama O; Ohishi T; Kato T; Suzuki K; Suzuki R
Eur Respir J; 2005 Mar; 25(3):528-33. PubMed ID: 15738299
[TBL] [Abstract][Full Text] [Related]
18. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias.
Churg A; Müller NL; Silva CI; Wright JL
Am J Surg Pathol; 2007 Feb; 31(2):277-84. PubMed ID: 17255773
[TBL] [Abstract][Full Text] [Related]
19. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis.
Bozkirli DE; Kozanoglu I; Bozkirli E; Yucel E
J Clin Apher; 2013 Dec; 28(6):422-5. PubMed ID: 23908096
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
